

[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI
[ Fri, Feb 19th 2021
] - WOPRAI

[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
David Lebovitz Maintained (BPMC) at Hold with Decreased Target to $105 on, Feb 18th, 2021
David Lebovitz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $112 to $105 on, Feb 18th, 2021.
David has made no other calls on BPMC in the last 4 months.
There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Konstantinos Aprilakis of "Stifel" Initiated at Hold and Held Target at $110 on, Thursday, December 3rd, 2020
- Eun Yang of "Jefferies" Downgraded from Strong Buy to Hold and Held Target at $96 on, Monday, November 2nd, 2020
These are the ratings of the 2 analyists that currently disagree with David
- Andrew Berens of "SVB Leerink" Maintained at Buy with Increased Target to $127 on, Tuesday, January 12th, 2021
- Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $120 on, Thursday, October 29th, 2020
Contributing Sources